The European Commission (EC) has approved MenQuadfi immunization of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria Meningitidis serogroups A, C, W and Y.
Invasive meningococcal disease (IMD) epidemiology has been a challenge because it is highly unpredictable and varies widely with different countries leaving room for outbreaks in unprotected and vulnerable populations.
MenQuadfi is now licensed by the Food and Drug Administration (FDA) in the United States for the prevention of IMD for children 2 years of age and older. The good news is, it is currently under review by several health authorities across the world to help meet local immunization efforts.
Read the full article